Aristeia Capital L.L.C. Buys Shares of 3,001 IQVIA Holdings Inc. (NYSE:IQV)

Aristeia Capital L.L.C. purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,001 shares of the medical research company’s stock, valued at approximately $635,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in IQVIA by 60.0% during the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 34,860 shares of the medical research company’s stock worth $7,371,000 after acquiring an additional 13,071 shares in the last quarter. Semmax Financial Advisors Inc. increased its holdings in IQVIA by 12.1% during the second quarter. Semmax Financial Advisors Inc. now owns 16,402 shares of the medical research company’s stock valued at $3,468,000 after buying an additional 1,771 shares during the period. Marshall Wace LLP lifted its holdings in IQVIA by 567.0% during the second quarter. Marshall Wace LLP now owns 77,610 shares of the medical research company’s stock worth $16,410,000 after buying an additional 65,974 shares during the period. Providence Capital Advisors LLC boosted its position in IQVIA by 60.6% during the 2nd quarter. Providence Capital Advisors LLC now owns 21,767 shares of the medical research company’s stock valued at $4,602,000 after acquiring an additional 8,216 shares in the last quarter. Finally, Farallon Capital Management LLC increased its holdings in shares of IQVIA by 3.1% in the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after acquiring an additional 86,870 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

IQV opened at $240.75 on Tuesday. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The firm has a 50 day moving average of $240.90 and a two-hundred day moving average of $233.81. The firm has a market capitalization of $43.86 billion, a PE ratio of 32.89, a P/E/G ratio of 2.25 and a beta of 1.49.

IQVIA (NYSE:IQV) last issued its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. During the same quarter last year, the company posted $2.22 earnings per share. The firm’s revenue was up 2.3% compared to the same quarter last year. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on IQV shares. Evercore ISI raised their price objective on IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research report on Tuesday, July 23rd. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Thursday, September 5th. The Goldman Sachs Group began coverage on shares of IQVIA in a research note on Thursday, June 6th. They issued a “buy” rating and a $270.00 target price for the company. Argus raised IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Finally, Royal Bank of Canada initiated coverage on IQVIA in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $267.00.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.